Heartflow (NASDAQ:HTFL) Shares Up 8.4% – Time to Buy?

Shares of Heartflow, Inc. (NASDAQ:HTFL) traded up 8.4% during mid-day trading on Tuesday . The company traded as high as $22.46 and last traded at $22.39. 1,844,682 shares changed hands during mid-day trading, an increase of 21% from the average session volume of 1,518,833 shares. The stock had previously closed at $20.66.

Wall Street Analyst Weigh In

HTFL has been the subject of a number of analyst reports. Wells Fargo & Company assumed coverage on Heartflow in a report on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 price target for the company. Canaccord Genuity Group raised their price target on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. boosted their price objective on shares of Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Stifel Nicolaus upped their price objective on shares of Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Heartflow presently has an average rating of “Moderate Buy” and an average target price of $38.50.

Heartflow Trading Up 1.3%

The company has a market capitalization of $2.04 billion and a PE ratio of -13.25. The stock has a 50-day moving average of $29.56.

Insiders Place Their Bets

In other Heartflow news, CEO John C.M. Farquhar sold 22,562 shares of the company’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total transaction of $619,552.52. Following the completion of the sale, the chief executive officer directly owned 591,656 shares in the company, valued at $16,246,873.76. This represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Campbell Rogers sold 65,153 shares of Heartflow stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $24.49, for a total value of $1,595,596.97. Following the completion of the transaction, the insider directly owned 76,034 shares in the company, valued at $1,862,072.66. This represents a 46.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 2,095,715 shares of company stock worth $58,533,709.

Institutional Trading of Heartflow

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. lifted its position in Heartflow by 463.9% during the fourth quarter. Invesco Ltd. now owns 577,397 shares of the company’s stock valued at $16,831,000 after buying an additional 475,004 shares in the last quarter. XTX Topco Ltd increased its position in shares of Heartflow by 282.6% in the fourth quarter. XTX Topco Ltd now owns 43,205 shares of the company’s stock worth $1,259,000 after acquiring an additional 31,913 shares in the last quarter. VARCOV Co. purchased a new position in shares of Heartflow in the 4th quarter valued at $1,657,000. Wellington Management Group LLP lifted its holdings in shares of Heartflow by 20.8% during the 4th quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock valued at $171,812,000 after acquiring an additional 1,014,006 shares in the last quarter. Finally, Catalio Capital Management LP purchased a new stake in Heartflow during the 4th quarter worth $3,319,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.